Pacira BioSciences, Inc. (PCRX): Entry into a Material Definitive Agreement
Pacira BioSciences, Inc. (PCRX) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. pcrx-20260628 6/28/2026 0001396814 false 0001396814 2026-06-28 2026-06-28 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event
How this was made
The 30-second read
Why it matters
The transaction provides an upfront payment plus revenue-based contingent milestones, with an expected close in Q3 2026. Traders can update deal valuation, probability-weighted cash flows, and risk around milestone achievement.
Market read
A disclosed M&A divestiture with quantified upfront and contingent consideration is a direct catalyst for PCRX deal-value expectations ahead of a Q3 2026 close.
What to watch
Closing is subject to customary conditions and includes post-closing restrictive covenants; any regulatory/operational friction could delay timing and affect deal probability.
Background
Pacira BioSciences (PCRX) filed an 8-K describing entry into a material definitive agreement to sell its wholly owned subsidiary and related assets tied to handheld cryoanalgesia devices (including iovera).
Ticker impact
Pacira BioSciences entered a Stock and Asset Purchase Agreement to divest its handheld cryoanalgesia/iovera business for up to $140M.
Likely positive near-term bias as investors price in the upfront consideration and de-risking of the iovera handheld business, with volatility around contingent milestone assumptions.
The filing discloses specific consideration amounts, revenue-based contingent milestones through 2031, and an expected closing window (Q3 2026), which are directly tradable inputs for deal-spread and probability-weighting models.
Market effects
Signals continued portfolio reshaping in medtech/biopharma devices toward handheld cryoanalgesia assets and revenue-milestone deal structures.
Limited direct regional impact; transaction is company-specific with US-listed issuer.
Moderate—Zimmer Biomet’s subsidiary is the buyer, but the disclosure is primarily about PCRX asset divestiture economics.
Counterpoint
Contingent consideration is tied to iovera revenue thresholds through 2031; if investors doubt trajectory, the headline $140M may be discounted heavily.
Key entities
- public_companyPacira BioSciences, Inc.
Seller of handheld cryoanalgesia/iov er a-related assets under a Stock and Asset Purchase Agreement.
- public_company_subsidiaryZimmer, Inc. (subsidiary of Zimmer Biomet Holdings, Inc.)
Purchaser of the iovera handheld cryoanalgesia business assets from Pacira.
- subsidiaryPacira CryoTech, Inc.
Wholly owned subsidiary whose stock is included in the divestiture.
